Riversand and Gecko Robotics are starting of 2020 with fresh funds for scaling business. Pexels

Two Houston tech companies are starting off 2020 with fresh funds in their pockets — to the tune of millions and millions of dollars.

Houston-based Riversand raised an additional $10 million last month, and Gecko Robotics, which has an office in Houston, closed a $40 million series B round.

In early December, Crestline Investors invested $10 million into Riversand, which specializes in Master Data Management and Product Information Management software solutions. In 2017, Crestline put $35 million into Riversand's series A round. According to a press release, the additional funds will be used to continue the software-as-a-service company's growth.

"Crestline Investors is a valued partner and has enabled us to deliver a best-in-class product that is seeing incredible adoption and high levels of customer satisfaction," says Upen Varanasi, CEO and founder of Riversand, in a news release. "We will use this additional capital to continuously strengthen our product through innovation, amplify our sales and marketing efforts, and accelerate growth in new geographies and market verticals."

Meanwhile, Gecko raised $40 million in its series B round in December to scale its business plans. The company has grown from 45 to 115 employees in the past year, per a news release. The company will continue to hire.

The round was led by Drive Capital, and had contributions from Founders Fund, Next47, and Y-Combinator.

"We are growing fast solving a critical infrastructure problems that affect our lives, and can even save lives," says Jake Loosararian, Gecko Robotics' co-founder and CEO, in a news release. "At our core, we are a robot-enabled software company that helps stop life threatening catastrophes. We've developed a revolutionary way to use robots as an enabler to capture data for predictability of infrastructure; reducing failure, explosions, emissions and billions of dollars of loss each year."

Gecko Robotics - industrial inspection Gecko Robotics focuses on industrial solutions. Photo via the release

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.